Arleen Paulino, Executive Vice President of Operations at Amgen Inc., filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 20, 2026, reporting securities held as of the event date of November 16, 2026.

Key Highlights

  • Reporting person: Arleen Paulino, identified as EVP, Operations at Amgen Inc. (NASDAQ:AMGN).
  • Direct common stock: 4,455 shares held directly, including 2,181 Restricted Stock Units (RSUs) and 66 Dividend Equivalents (DEs) under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.
  • Indirect common stock: 2,039.9774 shares held indirectly through the company's 401(k) Plan, representing interests in the company's stock fund.
  • Non-qualified stock options (NQSOs): Eight separate NQSO grants covering a total of 81,265 shares of common stock, with exercise prices ranging from $230.15 to $329.59.
  • Event date: November 16, 2026, triggering the initial Section 16(a) beneficial ownership report.
  • Largest single option grant: 40,595 NQSOs exercisable at $230.15, expiring August 6, 2031, all of which are reported as fully vested and exercisable.

Paulino's Initial Beneficial Ownership Position at Amgen

According to the filing, Arleen Paulino directly owns 4,455 shares of Amgen common stock. The filing discloses that this total includes 2,181 RSUs granted under the Equity Incentive Plan, which "will be paid in shares of the Company's common stock on a one-to-one basis" upon vesting, as well as 66 Dividend Equivalents credited on unvested RSUs and paid out in shares along with a cash payment for any remaining fractional share amount. An additional 2,039.9774 shares are held indirectly through the Amgen 401(k) Plan, representing interests in the company's stock fund as of the filing date.

The filing reports eight NQSO grants in Table II. Four of those grants are reported as fully vested and immediately exercisable: 5,314 shares at $236.36 (expiring May 5, 2030), 5,434 shares at $239.64 (expiring April 30, 2031), 40,595 shares at $230.15 (expiring August 6, 2031), and 7,070 shares at $230.92 (expiring May 2, 2032). The remaining four grants are partially or entirely unvested. The grant of 7,166 shares at $235.97 is partially vested with 4,729 options exercisable, and the remaining portion vests on May 2, 2027. Two additional grants of 4,326 shares at $300.30 and 6,214 shares at $270.44 are each partially vested, with remaining installments commencing May 7, 2027, and May 6, 2027, respectively. A final grant of 5,146 shares at $329.59 will vest in four equal annual installments of 25% each, commencing May 5, 2027.

The form was signed by Andrea A. Robinson as attorney-in-fact for Ms. Paulino and was filed on November 20, 2026, as indicated in the filing.

What Was Disclosed

Arleen Paulino submitted her initial beneficial ownership statement as EVP, Operations of Amgen Inc., disclosing direct ownership of 4,455 common shares, indirect 401(k) plan holdings of 2,039.9774 shares, and eight NQSO grants covering 81,265 underlying shares with exercise prices from $230.15 to $329.59.